Law 360 M&A

MARCH 21, 2024

A shareholder of liver disease-focused biopharmaceutical company CymaBay Therapeutics Inc. sued the company in Delaware Chancery Court to extract more information over a proposed $4.3 billion merger with Gilead Sciences Inc.,

52

52

Law 360 M&A

FEBRUARY 12, 2024

Gilead Sciences Inc. said Monday that it has agreed to purchase liver disease-focused clinical-stage biopharmaceutical company CymaBay Therapeutics Inc. billion in cash.

52

52

Benzinga

FEBRUARY 13, 2024

Monday, Gilead Sciences Inc (NASDAQ: GILD ) agreed to acquire CymaBay Therapeutics Inc (NASDAQ: CBAY ) for $32.50 The addition of CymaBay’s investigational lead product candidate, seladelpar for primary biliary cholangitis (PBC), including pruritus, complements Gilead’s existing liver portfolio.

Equity 52

Equity 52

Harvard Corporate Governance

JULY 4, 2022

Posted by Subodh Mishra, Institutional Shareholder Services, Inc., on Monday, July 4, 2022 Editor's Note: Subodh Mishra is Global Head of Communications at Institutional Shareholder Services, Inc. Voting results are based on filings by companies up to June 13, 2022. companies so far, compared to 561 in 2021.

251

251

Harvard Corporate Governance

NOVEMBER 21, 2023

It is the highest number of companies receiving Trendsetter status – over one-fifth of the S&P 500 companies evaluated – since the benchmarking study was expanded in 2015 from covering the S&P 100. There were 28 top-scoring companies then.) American Electric Power Company Inc.; Equinix Inc.;

Technology 133

Technology 133

Business Wire M&A

MAY 9, 2023

BUSINESS WIRE)--Gilead Sciences, Inc. Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for infl

52

52

Benzinga

AUGUST 7, 2023

07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. NASDAQ: IKNA , "Ikena")), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. Gilead Sciences acquired an equity stake in Pionyr through their 2020 option-to-acquire agreement. "We

Equity 40

Equity Finance 40